Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China.
Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Cardiovasc Drugs Ther. 2024 Aug;38(4):679-691. doi: 10.1007/s10557-023-07436-1. Epub 2023 Feb 4.
Obesity is mediated by the changes in dyslipidemia, oxidative stress, and inflammation, leading to vascular endothelial dysfunction. Glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 inhibitors prevent the development of endothelial dysfunction. However, the underlying mechanism still remains largely unclear. Long non-coding RNAs (lncRNAs), one class of non-coding small RNAs, have been shown to exert a regulatory impact on the endothelial function in obesity. This study aimed to investigate whether the elevation of GLP-1 by a DPP-4 inhibitor sitagliptin improved vascular endothelial function by modulating lncRNAs in obese mice and to clarify the underlying molecular mechanism.
Male C57BL/6J mice were fed a high-fat diet for 4 months to induce obesity and some obese mice were treated with sitagliptin for the last 1 month. Levels of total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and glucagon-like peptide-1 (GLP-1) in plasma were detected by ELISA. LncRNA expression profile was analyzed via microarray. Aortic relaxations were examined by myograph. Protein expressions and phosphorylations were determined using western blot. The differentially expressed lncRNAs were validated using qRT-PCR.
Obese mice exhibited increased levels of TC and LDL, decreased concentrations of HDL and GLP-1 in plasma, and impaired aortic endothelium-dependent relaxations; such effects could be reversed by sitagliptin. Moreover, the altered expression profile of lncRNAs in the obese mouse aortae could be modulated by sitagliptin. Consistent with microarray analysis, qRT-PCR also revealed that lncRNA ENSMUST00000213271 was up-regulated in obese mouse aortae and aortic endothelial cells (ECs), which could be down-regulated by sitagliptin. Creb5 silencing reduced lncRNA ENSMUST00000213271 in obese mouse ECs. Knockdown of either Creb5 or lncRNA ENSMUST00000213271 restored the activation of AMPK/eNOS in obese mouse ECs. Furthermore, sitagliptin also suppressed Creb5 and lncRNA ENSMUST00000213271 and increased the phosphorylations of AMPK and eNOS in obese mice.
Creb5/lncRNA ENSMUST00000213271 mediated vascular endothelial dysfunction through inhibiting AMPK/eNOS cascade in obesity. Elevation of GLP-1 by sitagliptin possibly improved endothelial function by suppressing Creb5/lncRNA ENSMUST00000213271 and subsequently restoring AMPK/eNOS activation in obese mice. This study will provide new evidence for the benefits of GLP-1 against vasculopathy in obesity.
肥胖是通过血脂异常、氧化应激和炎症的变化介导的,导致血管内皮功能障碍。胰高血糖素样肽-1(GLP-1)类似物和二肽基肽酶-4 抑制剂可预防内皮功能障碍的发生。然而,其潜在机制仍在很大程度上不清楚。长链非编码 RNA(lncRNA)作为一类非编码小分子 RNA,已被证明对肥胖中的内皮功能具有调节作用。本研究旨在探讨二肽基肽酶-4 抑制剂西他列汀通过调节肥胖小鼠中的 lncRNA 是否能提高 GLP-1 水平来改善血管内皮功能,并阐明潜在的分子机制。
雄性 C57BL/6J 小鼠喂食高脂肪饮食 4 个月以诱导肥胖,部分肥胖小鼠在最后 1 个月接受西他列汀治疗。通过 ELISA 检测血浆中总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和胰高血糖素样肽-1(GLP-1)的水平。通过微阵列分析检测 lncRNA 表达谱。通过肌动图检查主动脉松弛度。使用 Western blot 测定蛋白表达和磷酸化。使用 qRT-PCR 验证差异表达的 lncRNA。
肥胖小鼠表现出血浆 TC 和 LDL 水平升高,HDL 和 GLP-1 浓度降低,主动脉内皮依赖性松弛功能受损;这些作用可被西他列汀逆转。此外,西他列汀还可以调节肥胖小鼠主动脉中 lncRNA 的表达谱。与微阵列分析一致,qRT-PCR 还显示肥胖小鼠主动脉和主动脉内皮细胞(EC)中的 lncRNA ENSMUST00000213271 表达上调,而西他列汀可使其下调。Creb5 沉默减少了肥胖小鼠 EC 中的 lncRNA ENSMUST00000213271。Creb5 或 lncRNA ENSMUST00000213271 的敲低恢复了肥胖小鼠 EC 中 AMPK/eNOS 的激活。此外,西他列汀还抑制 Creb5 和 lncRNA ENSMUST00000213271,并增加肥胖小鼠中 AMPK 和 eNOS 的磷酸化。
Creb5/lncRNA ENSMUST00000213271 通过抑制肥胖中的 AMPK/eNOS 级联反应介导血管内皮功能障碍。西他列汀通过抑制 Creb5/lncRNA ENSMUST00000213271 并随后恢复肥胖小鼠中 AMPK/eNOS 的激活,可能改善 GLP-1 对肥胖症血管病变的内皮功能。本研究为 GLP-1 对肥胖症血管病变的益处提供了新的证据。